共 50 条
Managing HBV and HCV Infection Pre- and Post-liver Transplant
被引:1
|作者:
Kumar, Naveen
[1
]
Choudhary, Narendra S.
[2
]
机构:
[1] Narayana Hosp Delhi, Hepatol & Gastroenterol, Delhi, India
[2] Medanta Medicity, Hepatol, Sect 38, Gurgaon, Delhi Ncr, India
关键词:
HEPATITIS-B-VIRUS;
TENOFOVIR DISOPROXIL FUMARATE;
SUSTAINED VIROLOGICAL RESPONSE;
SOFOSBUVIR PLUS RIBAVIRIN;
ACTING ANTIVIRAL THERAPY;
C VIRUS;
IMMUNE GLOBULIN;
PEGYLATED-INTERFERON;
OPEN-LABEL;
PROPHYLAXIS WITHDRAWAL;
D O I:
10.1016/j.jceh.2023.09.008
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation. ( J CLIN EXP HEPATOL 2024;14:101287)
引用
收藏
页数:14
相关论文